OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer.
The FDA has granted fast track designation to the EGFR/HER3 bispecific antibody-drug conjugate (ADC) AVZO-1418 for treatment ...
Day One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc.Agreement provides for upfront consideration of $25.00 ...
Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug ...
CytomX Therapeutics, Inc.'s ADC candidate, CX-2051, shows promise in colorectal cancer. Click here to read an analysis of ...
Mersana Therapeutics' decision earlier this year to go all-in on its antibody-drug conjugate Emi-Le appears to have paid ...
Dr. Joshua Sabari sat down with Dr. Michael Cecchini to discuss advances in colorectal cancer management and key data ...
Day One Biopharmaceuticals, Inc. is rated a Strong Buy with robust product growth, pipeline expansion & strategic acquisition ...
A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with ...
Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback